The U.S. Food and Drug Administration approved the FoundationOne CDx, the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.
The post FDA Approves, CMS Proposes Coverage of First Test to Detect Extensive Number of Cancer Biomarkers appeared first on HealthcareNOWradio.com.